Amber Bio website screenshot

Amber Bio

Amber Bio is a San Francisco biotechnology company developing an RNA-based gene-editing platform capable of making multi-kilobase edits — rewriting thousands of bases on a single RNA strand in one step — to reach previously undruggable patient populations. Because edited RNA eventually degrades in the body, the approach is designed to be safer and reversible compared with permanent DNA editing. The platform pairs multi-kilobase RNA writing with AI foundation models to target diverse pathogenic variants across patients with a single product, initially focused on ophthalmology and central nervous system diseases. Founded by CRISPR-field researchers from the Broad Institute and UC Berkeley (co-founder and CTO Basem Al-Shayeb, advised by Nobel Laureate Jennifer Doudna), Amber Bio launched in 2023 with a $26M seed round co-led by Playground Global and Andreessen Horowitz. It has no public developer API; this API Evangelist profile tracks the company as a portfolio lead.

Amber Bio is profiled on the APIs.io network. Tagged areas include Company, Engineered Biology, RNA Editing, Gene Editing, and Genetic Medicine.

Amber Bio’s developer surface includes product news and 4 more developer resources.

🌐 Visit website 📡 Source on GitHub
6.8/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyEngineered BiologyRNA EditingGene EditingGenetic MedicineBiotechnologyCRISPRTherapeutics

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 6.8/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.0 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/amber-bio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Amber Bio Domain Security

TLSv1.3 · HSTS · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Company 3

The organization behind the API

Website
Website
 Careers
Careers
 News
News

Other 1

Properties that don't map to a standard resource type

Team
Team

Source (apis.yml)

apis.yml Raw ↑ 
aid: amber-bio
name: Amber Bio
description: Amber Bio is a San Francisco biotechnology company developing an RNA-based gene-editing platform capable of making
  multi-kilobase edits — rewriting thousands of bases on a single RNA strand in one step — to reach previously undruggable
  patient populations. Because edited RNA eventually degrades in the body, the approach is designed to be safer and reversible
  compared with permanent DNA editing. The platform pairs multi-kilobase RNA writing with AI foundation models to target diverse
  pathogenic variants across patients with a single product, initially focused on ophthalmology and central nervous system
  diseases. Founded by CRISPR-field researchers from the Broad Institute and UC Berkeley (co-founder and CTO Basem Al-Shayeb,
  advised by Nobel Laureate Jennifer Doudna), Amber Bio launched in 2023 with a $26M seed round co-led by Playground Global
  and Andreessen Horowitz. It has no public developer API; this API Evangelist profile tracks the company as a portfolio lead.
url: https://raw.githubusercontent.com/api-evangelist/amber-bio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- playground-global
x-tier: stub
x-tier-reason: portfolio-lead
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-17'
image: https://cdn.prod.website-files.com/6245f65e49aca16254e8bad8/624dc97fcb2b8c6590085e6f_OPG.png
tags:
- Company
- Engineered Biology
- RNA Editing
- Gene Editing
- Genetic Medicine
- Biotechnology
- CRISPR
- Therapeutics
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/amber-bio-domain-security.yml
- type: Website
  url: https://www.amber.bio/
- type: Careers
  url: https://www.amber.bio/careers
- type: News
  url: https://www.amber.bio/#news
- type: Team
  url: https://www.amber.bio/#team
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence